Granules gets USFDA nod for postpartum haemorrhage prevention drug
Granules India said its subsidiary has received approval from the US health regulator for Methylergonovine tablets, used for the prevention and control of postpartum haemorrhage
New Delhi: Drug firm Granules India on Thursday said its subsidiary has received approval from the US health regulator for Methylergonovine tablets, used for the prevention and control of postpartum haemorrhage.
In a filing to BSE, Granules India said “the US Food and Drug Administration (USFDA) has approved its abbreviated new drug applications (ANDA) for Methylergonovine 0.2 mg tablets. The ANDA was filed by Granules Pharmaceuticals Inc., a wholly owned subsidiary of Granules India Ltd”.
The approved product is the bioequivalent to the reference listed drug product Methergine 0.2 mg, it added.
Shares of Granules India were trading at Rs105.40 per scrip on BSE, up by 8.94%.
Track all market updates here
- RBI against independent regulator for payment systems outside central bank
- Germany’s transport authority orders Opel to recall 73,000 diesel vehicles worldwide
- RBI opens banking tap to ease liquidity crunch at NBFCs
- New RBI norms put mobile wallets on par with payments banks
- Imminent NBFC slowdown could lead to credit crunch
Editor's Picks »
- Policy rethink and higher volumes to aid container shippers
- DCB Bank delivers a strong Q2 but pressure on margins foreseen
- Havells India: Rising costs give a jolt to profitability in September quarter
- All’s well at Mindtree, except for high client concentration risk
- India’s rising steel demand is making companies starry-eyed